Detailed information for compound 593650
Basic information
Technical information
- TDR Targets ID: 593650
- Name: N-(4-pyridin-2-yl-1,3-thiazol-2-yl)pyridin-2- amine
- MW: 254.31 | Formula: C13H10N4S
-
H donors: 1
H acceptors: 3
LogP: 2.72
Rotable bonds: 3
Rule of 5 violations (Lipinski): 1 - SMILES: c1ccc(nc1)Nc1scc(n1)c1ccccn1
- InChi: 1S/C13H10N4S/c1-3-7-14-10(5-1)11-9-18-13(16-11)17-12-6-2-4-8-15-12/h1-9H,(H,15,16,17)
- InChiKey: RYCUBTFYRLAMFA-UHFFFAOYSA-N
Network
Hover on a compound node to display the structore
Synonyms
- N-[4-(2-pyridyl)thiazol-2-yl]pyridin-2-amine
- N-[4-(2-pyridyl)-2-thiazolyl]-2-pyridinamine
- 2-pyridyl-[4-(2-pyridyl)thiazol-2-yl]amine
- ZINC00257247
- BAS 00853877
- Pyridin-2-yl-(4-pyridin-2-yl-thiazol-2-yl)-amine
- BIM-0026443.P001
- CBMicro_026353
Targets
Known targets for this compound
| Species | Target name | Source | Bibliographic reference |
|---|---|---|---|
| Homo sapiens | potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 | Starlite/ChEMBL | References |
| Homo sapiens | methyl-CpG binding domain protein 2 | Starlite/ChEMBL | No references |
| Homo sapiens | potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 | Starlite/ChEMBL | References |
| Homo sapiens | potassium intermediate/small conductance calcium-activated channel, subfamily N, member 1 | Starlite/ChEMBL | References |
| Homo sapiens | methyl CpG binding protein 2 | Starlite/ChEMBL | No references |
Predicted pathogen targets for this compound
By orthology
By sequence similarity to non orthologous known druggable targets
| Species | Potential target | Known druggable target | Length | Alignment span | Identity |
|---|---|---|---|---|---|
| Plasmodium vivax | hypothetical protein, conserved | potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 | 231 aa | 188 aa | 21.3 % |
Obtained from network model
Ranking Plot
Putative Targets List
| Species | Potential target | Raw | Global | Species |
|---|---|---|---|---|
| Schistosoma mansoni | calcium-activated potassium channel | 0.0569799 | 1 | 1 |
| Schistosoma mansoni | hypothetical protein | 0.0569799 | 1 | 1 |
| Echinococcus granulosus | small conductance calcium activated potassium | 0.0569799 | 1 | 0.5 |
| Echinococcus multilocularis | small conductance calcium activated potassium | 0.0569799 | 1 | 0.5 |
| Loa Loa (eye worm) | hypothetical protein | 0.0569799 | 1 | 1 |
Activities
| Activity type | Activity value | Assay description | Source | Reference |
|---|---|---|---|---|
| Activity (functional) | NOVARTIS: Antimalarial liver stage activity measured as a greater than 50% reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells at 10uM compound concentration, determined by immuno-fluorescence. | ChEMBL. | 22096101 | |
| Activity (binding) | Inhibition of Kca3.1 channel expressed in HEK293 cells by thallium flux assay | ChEMBL. | 18774291 | |
| CC50 | = 18.63 uM | NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7) | ChEMBL. | 18579783 |
| CC50 (ADMET) | = 75.6 uM | Cytotoxicity in human KB cells assessed as cell viability incubated for 72 hrs by MTT assay | ChEMBL. | 26318065 |
| EC50 (functional) | = 0.0585 uM | NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay | ChEMBL. | 18579783 |
| EC50 (functional) | = 0.1141 uM | NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay | ChEMBL. | 18579783 |
| IC50 (binding) | = 1550 nM | BindingDB_Patents: Binding Assay. DNA binding assays using recombinant MBDs. To produce recombinant His6-tagged MBD polypeptides from human MBD2 (MBD2-MBD), MBD2-MBD cDNA was amplified from clone MGC-45084 (American Type Culture Collection), using PCR primers containing BamHI and EcoRI recognition sites (5'-GGATCCATGGAGAGCGGGAAGAGGATGGA-3' (SEQ ID NO:1) and 5'-GAATTCCATCTTTCCAGTTCTGAAGT-3' (SEQ ID NO:2)), and then introduced into pFBC6H, a modified pFastBac-1 baculovirus expression vector (Invitrogen), that had been linearized via cutting with EcoRI and XbaI. This pFB6H-MBD2 expression construct was used to transform DH10BacE. coli competent cells (Invitrogen) to form an MBD2 expression bacmid via site-specific transposition. The MBD2 expression bacmid was then transfected into Sf9 insect cells for production of recombinant MBD2 baculovirus particles, which were used to infect Sf9 cells (1 MOI, 48 hours) to generate recombinant MBD2 protein. | ChEMBL. | No reference |
| IC50 (binding) | = 0.025 uM | Displacement of [125I]apamin from Kca2.3 channel expressed in HEK293 cells by scintillation proximity assay | ChEMBL. | 18774291 |
| IC50 (binding) | = 0.043 uM | Inhibition of Kca2.1 channel expressed in HEK293 cells by thallium flux assay | ChEMBL. | 18774291 |
| IC50 (binding) | = 0.123 uM | Inhibition of Kca2.2 channel expressed in HEK293 cells by thallium flux assay | ChEMBL. | 18774291 |
| IC50 (binding) | = 0.29 uM | Inhibition of Kca2.3 channel expressed in HEK293 cells by electrophysiology assay | ChEMBL. | 18774291 |
| IC50 (binding) | = 0.543 uM | Inhibition of Kca2.3 channel expressed in HEK293 cells by thallium flux assay | ChEMBL. | 18774291 |
| IC50 (binding) | = 0.543 uM | Displacement of [125I]apamin from Kca2.2 channel expressed in HEK293 cells | ChEMBL. | 18774291 |
| IC50 (functional) | = 0.718 uM | DNDI | DNDI. | No reference |
| IC50 (functional) | = 2.1 uM | Antileishmanial activity against Leishmania donovani MHOM/IN/80/Dd8 expressing luciferase reporter gene infected in mouse J-774A1 cells assessed as inhibition of amastigote stage formation incubated for 72 hrs by luminometry | ChEMBL. | 26318065 |
| IC50 | > 10.42 uM | DNDI: Cytotoxicity against human MRC-5 lung fibroblast cells. | ChEMBL. | No reference |
| Inhibition (functional) | = -2.43 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmGT2 that are glucose transport deficient and complemented with the L. Mexicana glucose transporter 2. Activity is measured by by DNA content using SYBR green in vitro | ChEMBL. | No reference |
| Inhibition (functional) | = -0.62 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmGLUT1 that are glucose transport deficient and complemented with the human glucose transporter GLUT1. Activity is measured by DNA content using SYBR green in vitro | ChEMBL. | No reference |
| Inhibition (functional) | = 0.38 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmPfHT that are glucose transport deficient and complemented with the Plasmodium falciparum hexose transporter. Activity is measured by by DNA content using SYBR green in vitro | ChEMBL. | No reference |
| Inhibition (functional) | = 2 % | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 LDH activity, using an LDH reporter assay. Test compounds present at 2uM | ChEMBL. | 20485427 |
| Inhibition (functional) | = 45 % | GSK_TCMDC: Percent inhibition of human HepG2 cell line. Test compounds present at 10uM. | ChEMBL. | 20485427 |
| Inhibition (functional) | = 87 % | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM | ChEMBL. | 20485427 |
| Inhibition (binding) | = 89 % | Inhibition of Kca2.3 channel expressed in HEK293 cells at 30 uM by thallium flux assay | ChEMBL. | 18774291 |
| Inhibition (functional) | = 93 % | GSK_TCMDC: Inhibition of Plasmodium falciparum Dd2 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM | ChEMBL. | 20485427 |
| Inhibition frequency index (IFI) (functional) | = 8.51 | Inhibition Frequency Index (IFI) | GSK. | 20485427 |
| MIC99 (functional) | = 0.39 uM | Antitubercular activity against Mycobacterium tuberculosis H37Rv in GAST media with glycerol and alanine after 7 to 14 days by broth microdilution method | ChEMBL. | 24075144 |
| MIC99 (functional) | = 0.39 uM | Antitubercular activity against Mycobacterium tuberculosis H37Rv in Middlebrook 7H9 broth with butyrate after 7 to 14 days by broth microdilution method | ChEMBL. | 24075144 |
| MIC99 (functional) | = 0.78 uM | Antitubercular activity against Mycobacterium tuberculosis H37Rv in Middlebrook 7H9 broth with glucose after 7 to 14 days by broth microdilution method | ChEMBL. | 24075144 |
| Percent growth inhibition (functional) | = 2 % | Percent inhibition of P. falciparum lactate dehydrogenase activity (at 2 uM) | GSK. | 20485427 |
| Percent growth inhibition (functional) | = 45 % | Percent inhibition of HepG2 growth (at 10 uM) | GSK. | 20485427 |
| Percent growth inhibition (functional) | = 87 % | Percent inhibition of P. falciparum 3D7 growth (at 2 uM) | GSK. | 20485427 |
| Percent growth inhibition (functional) | = 93 % | Percent inhibition of P. falciparum Dd2 growth (at 2 uM) | GSK. | 20485427 |
| XC50 (functional) | = 5.94 | XC50 determination of P. falciparum 3D7 growth | GSK. | 20485427 |
| XC50 (functional) | = 1.14991 uM | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole erythrocytes, using parasite LDH activity as an index of growth. | ChEMBL. | 20485427 |
Phenotypes
Whole-cell/tissue/organism interactions
| Species name | Source | Reference | Is orphan |
|---|---|---|---|
| Leishmania donovani | ChEMBL23 | 26318065 | |
| Homo sapiens | ChEMBL23 | ||
| Plasmodium falciparum | ChEMBL23 | 18579783 | |
| Trypanosoma brucei gambiense |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
Annotated phenotypes:
We have no manually annotated phenotypes for this drug.
What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by
drugs, or by genetic manipulation of cells (e.g. gene knockouts or
knockdowns) is manually curated from the literature. These
descriptions help to describe the potential of the target for drug
development. If no information is available for this gene or if the
information is incomplete, this may mean that i) the papers
containing this information either appeared after the curation
effort for this organism was carried out or they were inadvertently
missed by curators; or that ii) the curation effort for this
organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
External resources for this compound
- ChEMBL: CHEMBL489770
- Search by GSK
Bibliographic References
2 literature references were collected for this gene.
If you have references for this compound, please enter them in a user comment (below) or Contact us.